Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy
Jordan S. F. Chan(University of Alberta), John R. Ussher(University of Alberta), Christina T. Saed(University of Alberta), N Wu(University of Alberta), Kunyan Yang(University of Alberta), Farah Eaton(University of Alberta), Amanda A. Greenwell(University of Alberta), Gregory R. Steinberg(McMaster University Medical Centre), Linyue Dong(University of Alberta), Jason R.B. Dyck(University of Alberta), Keshav Gopal(University of Alberta), Indiresh A Mangra-Bala(University of Alberta), Magnus J. Stenlund(University of Alberta), Seyed Amirhossein Tabatabaei Dakhili(University of Alberta), Sally R Ferrari(University of Alberta), Tanin Shafaati(University of Alberta), Alexa N. King(University of Alberta)
Cited by 0
Related Papers
Lipogenesis inhibitors: therapeutic opportunities and challenges
|Nature Reviews Drug Discovery|2022|383
Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity
|Journal of Clinical Investigation|2011|331
Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte
|Journal of Biological Chemistry|2004|330
Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency
|Cardiovascular Research|2019|195
Whole Body Deletion of AMP-activated Protein Kinase β2 Reduces Muscle AMPK Activity and Exercise Capacity
|Journal of Biological Chemistry|2010|161